Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many ...
Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie ...
Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...
CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...
In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13 ...
The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a ...
AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...
Novo is threatening litigation in response to the move by the telehealth company to “unlawfully mass-market” what it called ...
Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...
The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is ...
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results